Spread | 0.30 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | -0.025295% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | 0.003377% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | GBP | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 119.95 |
Open | 121.81 |
1-Year Change | 4.08% |
Day's Range | 121.37 - 122.01 |
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.